Global Collaboration Uncovers GBA1 Risk Factor in West African Parkinson’s Patients
Precision medicine offers significant potential to improve treatment effectiveness and accelerate the development of new therapies, ultimately leading to more equitable healthcare. However, fully realizing this potential for all individuals wiht Parkinson’s disease requires a deeper understanding of the condition in diverse populations beyond those traditionally studied. This approach yields considerable benefits, as demonstrated by the 2023 discovery of the GBA1 risk factor for Parkinson’s disease in west Africa through a global research collaboration.1
GBA1 is a prevalent risk factor, found in over 40% of individuals with Parkinson’s disease in Nigeria.1 This finding highlights the importance of including diverse genetic backgrounds in Parkinson’s research. Historically, genetic studies have largely focused on individuals of European ancestry, perhaps overlooking crucial genetic variations that contribute to the disease in other populations.
The identification of GBA1 as a significant risk factor in West Africa underscores the genetic heterogeneity of Parkinson’s disease. Mutations in the GBA1 gene, which encodes the glucocerebrosidase enzyme, are known to increase the risk of developing Parkinson’s, even in individuals without a family history of the disease.2 The high prevalence of this risk factor in the Nigerian population suggests that genetic factors may play a particularly significant role in the development of Parkinson’s in this region.
Expanding research to include diverse populations is crucial for several reasons. It can reveal novel genetic risk factors, identify unique disease subtypes, and improve the accuracy of diagnostic tools. Furthermore, understanding how genetic background influences treatment response can pave the way for personalized therapies tailored to individual patients.3
The success of the West Africa GBA1 discovery serves as a model for future research endeavors. collaborative, international efforts that prioritize inclusivity and diversity are essential to unlock the full potential of precision medicine in Parkinson’s disease and ensure that all patients benefit from advancements in treatment and care.
References
- Genetic risk factor for Parkinson’s disease identified in West Africa. Nature Genetics. (2023).
- Parkinson’s Disease. National Institute of Neurological Disorders and Stroke.
- Parkinson’s Disease and Genetics. The Michael J.Fox Foundation for Parkinson’s Research.